Business
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending
About this update from Protara Therapeutics, Inc.
[{"type":"image","alt":"Protara Therapeutics","displaySize":"","headline":null,"caption":"Protara Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UG_sFiObOKNigh1f.P_1zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106}},"lazy":false},{"type":"text","content":"On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026","length":133,"tagName":"p"},{"type":"text","content":"Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026","length":116,"tagName":"p"},{"type":"text","content":"Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026","length":177,"tagName":"p"},{"type":"text","content":"Recently completed approximately $86 million public offering extending cash runway into 2028","length":92,"tagName":"p"},{"type":"text","content":"NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today highlighted recent updates and anticipated 2026 milestones.","length":260,"tagName":"p"},{"type":"text","content":"“On the heels of a remarkable year marked by meaningful progress across the entirety of our pipeline, we are entering 2026 with unwavering resolve to continue to execute on our mission to deliver transformative therapies to patients with cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “For our non-muscle invasive bladder cancer (NMIBC) program, our growing body of clinical data continue to support that TARA-002 could serve as a differentiated, easy to administer treatment option across the NMIBC treatment landscape. Following our recent ADVANCED-2 update in which TARA-002 demonstrated meaningful and durable activity in BCG-Naïve NMIBC patients, we look forward to providing an interim update on the registrational BCG-Unre...